Prostate-associated gene 4 (PAGE4)

Prostate-associated gene 4 (PAGE4) is an intrinsically disordered protein that functions as a stress-response protein and acts as a transcriptional coactivator, notably potentiating the activity of the oncogenic transcription factor c-Jun[1][3][5]. PAGE4 is a member of the cancer-testis antigen family with expression typically restricted to normal reproductive tissues (testis, fetal prostate) but is aberrantly re-expressed at high levels in prostate cancer, especially in early and localized stages[3][5]. Its key biological functions include suppressing reactive oxygen species production, protecting cells from DNA damage and oxidative stress, and modulating the MAPK signaling pathway. PAGE4 is developmentally regulated and is post-translationally modified by phosphorylation, especially at threonine 51, which changes its interaction with c-Jun and potentially its transcriptional regulatory functions[5]. While considered a promising therapeutic target and biomarker for prostate cancer, no drugs currently target PAGE4 directly, but ongoing research continues to explore its potential utility in diagnosis, prognosis, and therapy for prostate cancer[3][5].

Other names

P antigen family member 4G antigen family C member 1PAGE-1GAGEC1JM27PAGE-4CT16.7GAGE-9

Not applicable (no specific drugs reported targeting PAGE4 as of now). Pharmacological targeting is proposed for prostate cancer therapy but remains experimental[3][5].